Jay B. Lusk

Mr. Jay B. Lusk

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2017 in Cancers
Verified
Journal Article
Open access
PDF file
JLJay B. Lusk
Jay B. Lusk
VLVanessa Y. M. Lam
Vanessa Y. M. Lam
NTNicholas Tolwinski
Nicholas Tolwinski
EGF signaling is a well-known oncogenic pathway in animals. It is also a key developmental pathway regulating terminal and dorsal-ventral patterning along with many other aspects of embryogenesis. In this review, we focus on the diverse roles for the EGF pathway in Drosophila embryogenesis. We review the existing body of evidence concerning EGF signaling in Drosophila embryogenesis focusing on current uncertainties in the field and areas for future study. This review provides a foundation for utilizing the Drosophila model system for research into EGF effects on cancer.

1 May 2023 in Stroke
Verified
Journal Article
Closed access
PDF file
DRDeborah Rose
Deborah Rose
ACAnnie Cavalier
Annie Cavalier
WKWayneho Kam
Wayneho Kam
SCSarah Cantrell
Sarah Cantrell
JLJay B. Lusk
Jay B. Lusk
BGBrian Mac Grory
Brian Mac Grory
Background: Prior systematic reviews have compared the efficacy of intravenous tenecteplase and alteplase in acute ischemic stroke, assigning their relative complications as a secondary objective. The objective of the present study is to determine whether the risk of treatment complications differs between patients treated with either agent. Methods: We performed a systematic review including interventional studies and prospective and retrospective, observational studies enrolling adult patients treated with intravenous tenecteplase for ischemic stroke (both comparative and noncomparative with alteplase). We searched MEDLINE, Embase, the Cochrane Library, Web of Science, and the www.ClinicalTrials.gov registry from inception through June 3, 2022. The primary outcome was symptomatic intracranial hemorrhage, and secondary outcomes included any intracranial hemorrhage, angioedema, gastrointestinal hemorrhage, other extracranial hemorrhage, and mortality. We performed random effects meta-analyses where appropriate. Evidence was synthesized as relative risks, comparing risks in patients exposed to tenecteplase versus alteplase and absolute risks in patients treated with tenecteplase. Results: Of 2226 records identified, 25 full-text articles (reporting 26 studies of 7913 patients) were included. Sixteen studies included alteplase as a comparator, and 10 were noncomparative. The relative risk of symptomatic intracranial hemorrhage in patients treated with tenecteplase compared with alteplase in the 16 comparative studies was 0.89 ([95% CI, 0.65–1.23]; I 2 =0%). Among patients treated with low dose (<0.2 mg/kg; 4 studies), medium dose (0.2–0.39 mg/kg; 13 studies), and high dose (≥0.4 mg/kg; 3 studies) tenecteplase, the RRs of symptomatic intracranial hemorrhage were 0.78 ([95% CI, 0.22–2.82]; I 2 =0%), 0.77 ([95% CI, 0.53–1.14]; I 2 =0%), and 2.31 ([95% CI, 0.69–7.75]; I 2 =40%), respectively. The pooled risk of symptomatic intracranial hemorrhage in tenecteplase-treated patients, including comparative and noncomparative studies, was 0.99% ([95% CI, 0%–3.49%]; I 2 =0%, 7 studies), 1.69% ([95% CI, 1.14%–2.32%]; I 2 =1%, 23 studies), and 4.19% ([95% CI, 1.92%–7.11%]; I 2 =52%, 5 studies) within the low-, medium-, and high-dose groups. The risks of any intracranial hemorrhage, mortality, and other studied outcomes were comparable between the 2 agents. Conclusions: Across medium- and low-dose tiers, the risks of complications were generally comparable between those treated with tenecteplase versus alteplase for acute ischemic stroke.

20 May 2025 in BMJ
Verified
Journal Article
Open access
BBBeau Blass
Beau Blass
CFCassie B Ford
Cassie B Ford
SSSamir Soneji
Samir Soneji
LZLindsay Zepel
Lindsay Zepel
TRTalita D’aGuiar Rosa
Talita D’aGuiar Rosa
JLJay B. Lusk
Jay B. Lusk
Objective: To determine the incidence and prevalence of dementia in a nationally representative cohort of US Medicare beneficiaries, stratified by important subgroups. Design: Population based study. Setting: Nationwide study between 2015 and 2021. Participants: Fee-for-service Medicare beneficiaries aged 66 or older with at least one year of continuous enrollment. Main outcome measures: Incidence and prevalence of dementia, calculated as percentage per person years or percentage of beneficiaries respectively. These metrics were also calculated in key subgroups defined by age, sex, race/ethnicity, and neighborhood socioeconomic status. Results: A total of 5 025 039 incident cases of dementia were documented from 2015 to 2021. The overall age and sex standardized incidence decreased between 2015 and 2021 from 3.5% to 2.8%. Prevalence increased during this time from 10.5% to 11.8%. Male beneficiaries had a higher age standardized incidence than did female beneficiaries in 2015 (3.5% v 3.4%), a difference that widened by 2021 (2.9% v 2.6%; estimated difference-in-difference 0.94, 95% confidence interval (CI) 0.94 to 0.95; P<0.001). Incidence was highest in 2015 for black beneficiaries (4.2%), followed by Hispanic beneficiaries (3.7%) and white beneficiaries (3.4%), and in 2021 for black beneficiaries (3.1%) followed by white beneficiaries (2.8%) and Hispanic beneficiaries (2.6%); the difference between white and black beneficiaries narrowed from 2015 to 2021 (difference-in-difference 0.92, 95% CI 0.91 to 0.93; P<0.001) as did the difference between white and Hispanic beneficiaries (difference-in-difference 0.88, 0.87 to 0.89; P<0.001). Conclusions: The incidence of dementia decreased from 2015 to 2021, but the prevalence increased. Disparities in these measures by race/ethnicity, sex, and neighborhood socioeconomic status should motivate future measures to promote health equity.

5 December 2022 in Alzheimer's & Dementia
Verified
Journal Article
Closed access
JLJay B. Lusk
Jay B. Lusk
CFCassie Ford
Cassie Ford
ACAmy G. Clark
Amy G. Clark
MGMelissa A. Greiner
Melissa A. Greiner
KJKim Johnson
Kim Johnson
EOEmily C. O'BRien
Emily C. O'BRien

20 August 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JLJay B. Lusk
Jay B. Lusk
BBBeau Blass
Beau Blass
HMHannah Mahoney
Hannah Mahoney
MHMolly N. Hoffman
Molly N. Hoffman
ACAmy G. Clark
Amy G. Clark
BHBradley G. Hammill
Bradley G. Hammill
Background: Understanding the relationship between neighborhood environment and cardiovascular outcomes is important to achieve health equity and implement effective quality strategies. We conducted a population‐based cohort study to determine the association of neighborhood socioeconomic deprivation and 30‐day mortality and readmission rate for patients admitted with common cardiovascular conditions. Methods and Results: We examined claims data from fee‐for‐service Medicare beneficiaries aged ≥65 years between 2017 and 2019 admitted for heart failure, valvular heart disease, ischemic heart disease, or cardiac arrhythmias. The primary exposure was the Area Deprivation Index; outcomes were 30‐day all‐cause death and unplanned readmission. More than 2 million admissions were included. After sequential adjustment for patient characteristics (demographics, dual eligibility, comorbidities), area health care resources (primary care clinicians, specialists, and hospital beds per capita), and admitting hospital characteristics (ownership, size, teaching status), there was a dose‐dependent association between neighborhood socioeconomic deprivation and 30‐day mortality rate for all conditions. In the fully adjusted model for death, estimated effect sizes of residence in the most disadvantaged versus least disadvantaged neighborhoods ranged from adjusted odds ratio 1.29 (95% CI, 1.22–1.36) for the heart failure group to adjusted odds ratio 1.63 (95% CI, 1.36–1.95) for the valvular heart disease group. Neighborhood deprivation was associated with increased adjusted 30‐day readmission rates, with estimated effect sizes from adjusted odds ratio 1.09 (95% CI, 1.05–1.14) for heart failure to adjusted odds ratio 1.19 (95% CI, 1.13–1.26) for arrhythmia. Conclusions: Neighborhood socioeconomic disadvantage was associated with 30‐day mortality rate and readmission for patients admitted with common cardiovascular conditions independent of individual demographics, socioeconomic status, medical risk, care access, or admitting hospital characteristics.

5 March 2022 in eClinicalMedicine
Verified
Journal Article
Open access
JLJay B. Lusk
Jay B. Lusk
HXHaolin Xu
Haolin Xu
LTLaine E. Thomas
Laine E. Thomas
LCLauren W. Cohen
Lauren W. Cohen
AHAdrian F. Hernandez
Adrian F. Hernandez
NBNadine J. Barrett
Nadine J. Barrett
The extent to which healthcare worker (HCWs) experiences during the COVID-19 pandemic vary by race or ethnicity after adjustment for confounding factors is not currently known. We performed an observational prospective cohort study of 24,769 healthcare workers from 50 U.S. states and the District of Columbia, enrolled between April 10, 2020 and June 30, 2021, and evaluated participant experiences during the COVID-19 pandemic, including testing, diagnosis with COVID-19, emotional experiences, burnout, and interest in vaccines and vaccine clinical trials. After adjustment for professional role, medical history, and community characteristics, Black and Asian participants were less likely to receive SARS-CoV-2 viral testing (adjusted odds ratio (aOR) 0·82 [0·70, 0·96], p=0·012 and aOR 0·77 [0·67, 0·89], p<0·001 respectively) than White participants. Hispanic participants were more likely to have evidence of COVID-19 infection (aOR 1·23 (1·00, 1·50, p=0·048). Black and Asian participants were less likely to report interest in a COVID-19 vaccine (aOR 0·11 [0·05, 0·25], p<0·001 and aOR 0·48 [0·27, 0·85] p=0·012). Black participants were less likely to report interest in participating in a COVID-19 vaccine trial (aOR = 0·39 [0·28, 0·54], p<0·001). Black participants were also less likely to report 3 or more daily emotional impacts of COVID-19 (aOR = 0·66 [0·53, 0·82], p=<0·001). Black participants were additionally less likely to report burnout (aOR = 0·66 ([0·49, 0·95], p=0·025). In a large, national study of healthcare workers, after adjustment for individual and community characteristics, race/ethnicity disparities in COVID-19 outcomes persist. Future work is urgently needed to understand precise mechanisms behind these disparities and to develop and implement targeted interventions to improve health equity for healthcare workers. This work was funded by the Patient-Centered Outcomes Research Institute (PCORI), Contract # COVID-19-2020-001.